Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibefradil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H known ✓ | O95180 | 10/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 1.00 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibefradil SCHEMBL22968530 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL6789173 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7265837 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL30170543 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL29364574 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL29359482 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL7708100 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL2230258 | 1.00 | CACNA1H (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL908985 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT | |
| Mibefradil SCHEMBL120810 | 0.99 | MAPT (1.00) | CACNA1HCACNA1CCYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8286 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12564590-B2 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | SYNDAX PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250295661-A1 | MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC. | 2025-09-25 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-0787711-B1 | Process for the preparation of alpha,beta-unsaturated carboxylic acids | HOFFMANN LA ROCHE (CH) | 2000-04-26 | — | — | EP | claimed |
| WO-2000018402-A1 | METHOD FOR TREATING ANDROGEN-RELATED CONDITIONS | MERCK & CO., INC. (US) | 2000-04-06 | — | — | WO | claimed |
| WO-2000002543-A2 | ANTIHYPERSENSITIVE COMBINATION OF VALSARTAN AND CALCIUM CHANNEL BLOCKER | NOVARTIS AG (CH) | 2000-01-20 | — | — | WO | claimed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | claimed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999011260-A1 | COMBINATION THERAPY COMPRISING ATORVASTATIN AND AN ANTIHYPERTENSIVE AGENT | PFIZER INC. (US) | 1999-03-11 | — | — | WO | claimed |
| CN-1162589-A | Process for manufacture of alpha-beta-unsaturated organic carboxylic acids | HOFFMANN LA ROCHE (CH) | 1997-10-22 | — | — | CN | claimed |
| EP-0787711-A2 | Process for the preparation of alpha,beta-unsaturated carboxylic acids | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | claimed |
| EP-0268148-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-11 | — | — | EP | claimed |
| US-4808605-A | Tetrahydronaphthalene derivatives as calcium antagonists | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | claimed |